title: Beta-blockers inhibit the modification of low-density lipoproteins by sodium hypochlorite in vitro.
abstract: The effect of beta-blockers (alprenolol, oxprenolol, atenolol, acebutolol) and the non-steroidal anti-inflammatory drug, diclofenac, on modification of low-density lipoproteins (LDL) by sodium hypochlorite (NaOCl) was investigated in vitro. Beta-blockers and diclofenac inhibit the formation of thiobarbituric acid reactive substances in LDL modified by NaOCl. Beta-blockers, but not diclofenac, inhibit the hypochlorite-induced aggregation of LDL which was determined by photon correlation spectroscopy. The intracellular accumulation of cholesterol esters in J774 macrophages is inhibited by addition of beta-blockers, but not diclofenac, to LDL prior to the addition of NaOCl. The modification inhibiting effect of beta-blockers is inversely correlated to the binding capabilities of these substances to LDL which were assessed by laser electrophoresis. Inhibition of LDL modification in vivo by beta-blockers may reduce the risk of atherosclerosis and, therefore, compensate for the cholesterol-raising effect of these drugs in human plasma.
authors.affiliation: Institute of Medical Physics and Biophysics, University of Leipzig, Germany.
authors.forename: T
authors.initials: T
authors.lastname: Seifert
authors.forename: O
authors.initials: O
authors.lastname: Zschörnig
authors.forename: J
authors.initials: J
authors.lastname: Arnhold
authors.forename: K
authors.initials: K
authors.lastname: Arnold
mesh_terms: D000070:Acebutolol / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000526:Alprenolol / Q000494:pharmacology; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D001161:Arteriosclerosis / Q000378:metabolism; D001262:Atenolol / Q000494:pharmacology; D015764:Bepridil / Q000031:analogs & derivatives / Q000378:metabolism; D001713:Biphenyl Compounds; D055598:Chemical Phenomena; D002621:Chemistry; D002788:Cholesterol Esters / Q000378:metabolism; D004008:Diclofenac / Q000494:pharmacology; D005609:Free Radicals / Q000378:metabolism; D006801:Humans; D008077:Lipoproteins, LDL / Q000378:metabolism*; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism; D015394:Molecular Structure; D010096:Oxprenolol / Q000494:pharmacology; D010316:Particle Size; D010851:Picrates; D012973:Sodium Hypochlorite / Q000494:pharmacology*; D013057:Spectrum Analysis; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism
chemical_list: D000319:Adrenergic beta-Antagonists; D000894:Anti-Inflammatory Agents, Non-Steroidal; D001713:Biphenyl Compounds; D002788:Cholesterol Esters; D005609:Free Radicals; D008077:Lipoproteins, LDL; D010851:Picrates; D017392:Thiobarbituric Acid Reactive Substances; D004008:Diclofenac; D001262:Atenolol; D010096:Oxprenolol; D000070:Acebutolol; D015764:Bepridil; D000526:Alprenolol; C004931:1,1-diphenyl-2-picrylhydrazyl; D012973:Sodium Hypochlorite